The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.
 
Tracy Lynn Rose
No Relationships to Disclose
 
David D. Chism
Stock and Other Ownership Interests - Biogen (I)
Travel, Accommodations, Expenses - Lilly
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Allison Mary Deal
No Relationships to Disclose
 
Susan Maygarden
No Relationships to Disclose
 
Young E. Whang
Research Funding - Astellas Pharma (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Tokai Pharmaceuticals (Inst)
 
Jordan Kardos
No Relationships to Disclose
 
Anthony Drier
No Relationships to Disclose
 
William Y. Kim
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Johnson & Johnson; Medivation
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier
 
Matthew I. Milowsky
Research Funding - Acerta Pharma (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Incyte (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Roche/Genentech